Inovio Pharmaceuticals, Inc. (INO)
9.25 +0.06 (0.65%)
After hours: 5:39PM EST
- PR Newswire
INOVIO to Present at Upcoming Investor Conferences in March
INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced that Dr. J. Joseph Kim, President and CEO, along with other members of INOVIO management, will present at the following investor conferences in March:
- PR Newswire
Geneos Therapeutics Secures $12 Million in Series A1 Financing to Advance Personalized Cancer Immunotherapy Programs
Geneos Therapeutics, a clinical stage company focused on the development of tumor neoantigen targeted personalized immunotherapies for cancer, announced today that it has closed its Series A1 round, raising $12 million in financing. The financing was led by Korea Investment Partners (KIP) – Global Bio Fund with strong participation from all existing Series A investors including, notably, Santé Ventures and Inovio Pharmaceuticals, Inc. (NASDAQ: INO). The new investment follows the previously announced initial financing of $10.5 million in February 2019. In conjunction with the financing, Mr. Sangwoo Lee, Managing Director Korea Investment Partners – USA Inc. joined Geneos' Board of Directors.
- Motley Fool
Why Inovio Stock Is Tanking Today
What happened Shares of Inovio Pharmaceuticals (NASDAQ: INO) were tanking by 10.3% as of 11:08 a.m. EST on Tuesday. The decline came after the company provided its fourth-quarter update following the market close on Monday.
